MedPath

Atazanavir

Generic Name
Atazanavir
Brand Names
Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
Drug Type
Small Molecule
Chemical Formula
C38H52N6O7
CAS Number
198904-31-3
Unique Ingredient Identifier
QZU4H47A3S
Background

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.

Indication

Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Phase 3
Completed
Conditions
HIV
Interventions
First Posted Date
2011-04-14
Last Posted Date
2018-11-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
160
Registration Number
NCT01335698
Locations
🇺🇸

SUNY Upstate Medical University, Syracuse, New York, United States

🇬🇧

Local Institution, Birmingham, WEST Midlands, United Kingdom

🇺🇸

Children'S National Medical Center, Washington, District of Columbia, United States

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Phase 4
Completed
Conditions
HIV, Combination Therapy
Interventions
Drug: Tenofovir/Emtricitabine
First Posted Date
2011-04-11
Last Posted Date
2015-02-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
132
Registration Number
NCT01332227
Locations
🇺🇸

Health For Life Clinic Pllc, Little Rock, Arkansas, United States

🇺🇸

Eisenhower Medical Center, Palm Springs, California, United States

🇺🇸

Consultive Medicine, Daytona Beach, Florida, United States

and more 6 locations

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

First Posted Date
2011-01-12
Last Posted Date
2014-12-16
Lead Sponsor
Juan A. Arnaiz
Target Recruit Count
180
Registration Number
NCT01274780
Locations
🇪🇸

Hospital Clinic, Barcelona, Spain

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

Phase 3
Withdrawn
Conditions
HIV
Interventions
First Posted Date
2010-12-07
Last Posted Date
2012-11-08
Lead Sponsor
ANRS, Emerging Infectious Diseases
Registration Number
NCT01255371
Locations
🇹🇿

NIMR-Mbeya Medical Research Program-Mbeya Referral Hospital, Mbeya, Tanzania

🇿🇦

Tshepang clinic, Limpopo University, Pretoria, South Africa

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Phase 4
Completed
Conditions
HIV
Interventions
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
First Posted Date
2010-11-02
Last Posted Date
2012-08-31
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
25
Registration Number
NCT01232127
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Completed
Conditions
Human Immunodeficiency Virus
Interventions
Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Drug: tenofovir/emtricitabine (TDF/FTC)
Procedure: Phlebotomy
First Posted Date
2010-08-11
Last Posted Date
2014-12-02
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
85
Registration Number
NCT01180075
Locations
🇺🇸

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Phase 4
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
First Posted Date
2010-04-13
Last Posted Date
2013-11-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
297
Registration Number
NCT01102972
Locations
🇵🇷

GSK Investigational Site, San Juan, Puerto Rico

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

First Posted Date
2010-04-07
Last Posted Date
2018-05-24
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
82
Registration Number
NCT01099579
Locations
🇹🇭

Local Institution, Bangkok, Thailand

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

Phase 3
Completed
Conditions
HIV
Interventions
Drug: Tenofovir/Emtricitabine
Drug: Atazanavir/Ritonavir
First Posted Date
2009-10-29
Last Posted Date
2017-05-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
710
Registration Number
NCT01003990
Locations
🇵🇷

Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico

🇺🇸

Sbma Research, Llc, Miami Beach, Florida, United States

🇺🇸

St Francis Memorial Hospital, San Francisco, California, United States

and more 12 locations

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

First Posted Date
2009-09-16
Last Posted Date
2015-08-07
Lead Sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Target Recruit Count
168
Registration Number
NCT00977756
Locations
🇺🇸

South Florida CDC Ft Lauderdale NICHD CRS (5055), Fort Lauderdale, Florida, United States

🇺🇸

New Jersey Medical School (NJ) (2802), Newark, New Jersey, United States

🇺🇸

SUNY Stony Brook NICHD CRS (5040), Stony Brook, New York, United States

and more 32 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy